Peter Riederer
Overview
Explore the profile of Peter Riederer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
235
Citations
6819
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grunblatt E, Yde Ohki C, Schmitt-Bohrer G, Riederer P, Walitza S
J Neural Transm (Vienna)
. 2025 Feb;
PMID: 39932549
Neurodegenerative diseases raise public health concerns. Recent evidence indicates that Alzheimer's disease (AD) sufferers will triple by 2050. The rising incidence of dementia diagnoses raises concerns about the socio-economical and...
2.
Sian-Hulsmann J, Riederer P, Michel T
Biomedicines
. 2025 Jan;
12(12.
PMID: 39767747
Despite many years of research into the complex neurobiology of Parkinson's disease, the precise aetiology cannot be pinpointed down to one causative agent but rather a multitude of mechanisms. Current...
3.
Naoi M, Maruyama W, Shamoto-Nagai M, Riederer P
J Neural Transm (Vienna)
. 2024 Dec;
132(3):387-406.
PMID: 39621110
Monoamine oxidase catalyzes oxidative deamination of monoamine transmitters and plays a critical role in the pathogenesis of neuropsychiatric diseases. Monoamine oxidase is classified into type A and B (MAO-A, MAO-B)...
4.
Riederer P, Hirsch E
J Neural Transm (Vienna)
. 2024 Nov;
131(12):1363-1365.
PMID: 39499330
No abstract available.
5.
Strobel S, Sian-Hulsmann J, Tappe D, Jellinger K, Riederer P, Monoranu C
Cells
. 2024 Sep;
13(18.
PMID: 39329695
Postencephalitic parkinsonism (PEP) is suggested to show a virus-induced pathology, which is different from classical idiopathic Parkinson's disease (PD) as there is no α-synuclein/Lewy body pathology. However, PEP shows a...
6.
Muller T, Gerlach M, Hefner G, Hiemke C, Jost W, Riederer P
J Neural Transm (Vienna)
. 2024 Sep;
131(10):1247-1262.
PMID: 39227478
A patient-tailored therapy of the heterogeneous, neuropsychiatric disorder of Parkinson's disease (PD) aims to improve dopamine sensitive motor symptoms and associated non-motor features. A repeated, individual adaptation of dopamine substituting...
7.
Leupold D, Buder S, Pfeifer L, Szyc L, Riederer P, Strobel S, et al.
Int J Mol Sci
. 2024 Aug;
25(15).
PMID: 39126026
Melanin is a crucial pigment in melanomagenesis. Its fluorescence in human tissue is exceedingly weak but can be detected through advanced laser spectroscopy techniques. The spectral profile of melanin fluorescence...
8.
Sian-Hulsmann J, Riederer P
J Neural Transm (Vienna)
. 2024 Jan;
131(12):1429-1453.
PMID: 38261034
Fascinatingly, an abundance of recent studies has subscribed to the importance of cytotoxic immune mechanisms that appear to increase the risk/trigger for many progressive neurodegenerative disorders, including Parkinson's disease (PD),...
9.
Kagerer S, Awasthi S, Ripke S, Maceski A, Benkert P, Fall A, et al.
Alzheimers Dement (Amst)
. 2024 Jan;
16(1):e12504.
PMID: 38213949
Introduction: Establishing valid diagnostic strategies is a precondition for successful therapeutic intervention in Alzheimer's disease (AD). Methods: One hundred forty-four healthy 75-year-old participants from the Vienna-Transdanube-Aging longitudinal cohort study were...
10.
Naoi M, Maruyama W, Shamoto-Nagai M, Riederer P
J Neural Transm (Vienna)
. 2024 Jan;
131(6):639-661.
PMID: 38196001
Parkinson's disease is characterized by its distinct pathological features; loss of dopamine neurons in the substantia nigra pars compacta and accumulation of Lewy bodies and Lewy neurites containing modified α-synuclein....